MX2010011224A - Derivados de quinoleina como inhibidores de la cinasa axl. - Google Patents
Derivados de quinoleina como inhibidores de la cinasa axl.Info
- Publication number
- MX2010011224A MX2010011224A MX2010011224A MX2010011224A MX2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A MX 2010011224 A MX2010011224 A MX 2010011224A
- Authority
- MX
- Mexico
- Prior art keywords
- quinolin
- yloxy
- dimethoxy
- phenyl
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4539808P | 2008-04-16 | 2008-04-16 | |
| PCT/EP2009/002798 WO2009127417A1 (en) | 2008-04-16 | 2009-04-16 | Quinoline derivatives as axl kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010011224A true MX2010011224A (es) | 2011-02-25 |
Family
ID=40999731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010011224A MX2010011224A (es) | 2008-04-16 | 2009-04-16 | Derivados de quinoleina como inhibidores de la cinasa axl. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9206130B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2262772B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5746015B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101325237B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102131783A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009237938A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2718538A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2391373T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL208103A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010011224A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010146474A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009127417A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| ITRM20100537A1 (it) | 2010-10-12 | 2012-04-12 | Consiglio Nazionale Ricerche | Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia |
| PT2780338T (pt) | 2011-11-14 | 2017-02-17 | Ignyta Inc | Derivados de uracil como inibidores da quinase axl e c-met |
| JP6006241B2 (ja) | 2012-01-31 | 2016-10-12 | 第一三共株式会社 | ピリドン誘導体 |
| CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
| CA2922542A1 (en) * | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| EP3074390B1 (en) | 2013-11-27 | 2020-07-08 | SignalChem Lifesciences Corporation | Aminopyridine derivatives as tam family kinase inhibitors |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| US10208034B2 (en) | 2014-12-25 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| WO2017146236A1 (ja) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| KR102558066B1 (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
| CN108250200A (zh) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
| WO2018139527A1 (ja) | 2017-01-26 | 2018-08-02 | 小野薬品工業株式会社 | キノリン誘導体のエタンスルホン酸塩 |
| WO2019039525A1 (ja) | 2017-08-23 | 2019-02-28 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含むがん治療剤 |
| SG11202001664VA (en) * | 2017-08-31 | 2020-03-30 | Abbvie Inc | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| IL273579B2 (en) | 2017-09-27 | 2025-10-01 | Incyte Corp | Salts of pyrrolizidine derivatives used as Tm inhibitors. |
| WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| HRP20250676T1 (hr) | 2018-06-29 | 2025-08-01 | Incyte Corporation | Formulacije inhibitora axl/mer |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
| AU2021268210A1 (en) * | 2020-05-08 | 2022-12-15 | Georgiamune, Inc. | Akt3 modulators |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| EP1153920B1 (en) * | 1999-01-22 | 2003-10-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| ES2436888T3 (es) * | 2003-09-26 | 2014-01-07 | Exelixis, Inc | Moduladores c-Met y métodos de uso |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| US20100234371A1 (en) * | 2005-08-22 | 2010-09-16 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| CA2655128A1 (en) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
| PL2101759T3 (pl) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
-
2009
- 2009-04-16 WO PCT/EP2009/002798 patent/WO2009127417A1/en not_active Ceased
- 2009-04-16 US US12/933,070 patent/US9206130B2/en active Active
- 2009-04-16 CN CN2009801129869A patent/CN102131783A/zh active Pending
- 2009-04-16 MX MX2010011224A patent/MX2010011224A/es not_active Application Discontinuation
- 2009-04-16 KR KR1020107023097A patent/KR101325237B1/ko active Active
- 2009-04-16 CA CA2718538A patent/CA2718538A1/en not_active Abandoned
- 2009-04-16 EP EP09731679A patent/EP2262772B8/en active Active
- 2009-04-16 AU AU2009237938A patent/AU2009237938A1/en not_active Abandoned
- 2009-04-16 RU RU2010146474/04A patent/RU2010146474A/ru not_active Application Discontinuation
- 2009-04-16 JP JP2011504377A patent/JP5746015B2/ja active Active
- 2009-04-16 ES ES09731679T patent/ES2391373T3/es active Active
-
2010
- 2010-09-13 IL IL208103A patent/IL208103A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP5746015B2 (ja) | 2015-07-08 |
| KR101325237B1 (ko) | 2013-11-04 |
| KR20100132038A (ko) | 2010-12-16 |
| JP2011517689A (ja) | 2011-06-16 |
| US9206130B2 (en) | 2015-12-08 |
| EP2262772B8 (en) | 2013-03-13 |
| RU2010146474A (ru) | 2012-05-27 |
| IL208103A0 (en) | 2010-12-30 |
| CA2718538A1 (en) | 2009-10-22 |
| US20110092503A1 (en) | 2011-04-21 |
| AU2009237938A1 (en) | 2009-10-22 |
| WO2009127417A1 (en) | 2009-10-22 |
| IL208103A (en) | 2015-08-31 |
| ES2391373T3 (es) | 2012-11-23 |
| EP2262772A1 (en) | 2010-12-22 |
| CN102131783A (zh) | 2011-07-20 |
| EP2262772B1 (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010011224A (es) | Derivados de quinoleina como inhibidores de la cinasa axl. | |
| JP6126233B2 (ja) | 新たなキノリン類の化合物及びその使用 | |
| US8211901B2 (en) | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | |
| JP4521428B2 (ja) | インドールスルホンアミド化合物 | |
| EP1692124B1 (en) | Biaryl sulfonamides as mmp inhibitors | |
| EP4082538A1 (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| BRPI1011994B1 (pt) | derivados de naftaleno carboxamida como inibidores de proteína quinase e histona desacetilase, métodos de preparação e usos | |
| JP2009526034A (ja) | デュシェンヌ型筋ジストロフィーの治療 | |
| TW200407112A (en) | Immunity-related protein kinase inhibitors | |
| CN106478606B (zh) | N-取代吲哚类衍生物及其应用 | |
| CN106478621B (zh) | 喹啉或喹唑啉类衍生物、制备方法及其应用 | |
| CN105218532B (zh) | 苯并三氮唑类化合物、制备方法和其医药用途 | |
| CN108530426A (zh) | 含喹喔啉酮的4-苯氧基取代喹啉类化合物及其应用 | |
| WO2017045271A1 (zh) | 苯并呋喃类衍生物、其制备方法及其治疗作用 | |
| CN105461687B (zh) | 含二氢哒嗪酮的喹啉类化合物及其用途 | |
| Sun et al. | Novel piperazine-1, 2, 3-triazole leads for the potential treatment of pancreatic cancer | |
| WO2023061051A1 (zh) | 一种磺酰胺类usp8抑制剂及其应用 | |
| CN117343046A (zh) | 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用 | |
| HK1156952A (en) | Quinoline derivatives as axl kinase inhibitors | |
| CN110407769B (zh) | 3,4-二氢-苯并[f][1,4]硫氮杂䓬-5(2H)-酮类化合物及其药物用途 | |
| CN104086530A (zh) | 4-取代喹啉类化合物及其应用 | |
| Zhang et al. | Zhijian Li2, 4, Huiran Qiu1, 4, Wenxia Lu1, 4, Namin Duan2, 4, Shule Fan1, Rui Zhou2, Xiangzhi Li1 | |
| HK40074114A (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| HK40074114B (en) | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | |
| WO2014190872A1 (zh) | 一种含硒化合物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |